{
  "id": 2093987,
  "title": "AMLX Stock Soars as Amylyx GLP-1 Drug Succeeds in Late-Stage Trial",
  "url": "https://urgent.news/2026/08/18/amlx-stock-soars-as-amylyx-glp-1-drug-succeeds-in-late-stage-trial",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-18T20:10:19.000Z",
  "source": {
    "name": "Yahoo Finance",
    "slug": "yahoo-finance",
    "url": "https://finance.yahoo.com/healthcare/articles/amlx-stock-soars-amylyx-glp-201019873.html"
  },
  "original_language": "en",
  "account": "Amylyx (AMLX) stock experienced a significant surge on Tuesday following the company's announcement of promising Phase 3 clinical trial results for its candidate drug, avexitide. The pharmaceutical firm reported in its press release that avexitide, a first-in-class GLP-1 receptor antagonist for post-bariatric hypoglycemia, demonstrated a 55% reduction in hypoglycemic events during the Lucidity trial. Amylyx shares are now trading at nearly three times their price at the start of the year, reflecting the substantial clinical and commercial milestone achieved by the Lucidity trial. With no FDA-approved treatments currently available for post-bariatric surgery hypoglycemia, avexitide holds Breakthrough Therapy and Orphan Drug designations. Amylyx now plans to submit a new drug application (NDA) for avexitide by the end of 2026, aiming for a commercial launch in the following year with a projected multi-year cash runway extending into 2028. The Lucidity trial's success, combined with the drug's clean safety profile, has made AMLX shares an attractive growth opportunity for investors.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}